-
Product Insights
NewNet Present Value Model: Cybin Inc’s CYB-003
Empower your strategies with our Net Present Value Model: Cybin Inc's CYB-003 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Thematic Analysis
NewPsychedelics Therapeutics Development and Trends, 2024
This report provides a summary of the current and future state of the psychedelic therapeutic sector, offering a high-level analysis of key trends and developments within the industry, including regulatory, clinical, and market dynamics. The report identifies the broader changes within the evolving psychedelic industry, facilitating informed decision-making for relevant sectors.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SPL-028 in Generalized Anxiety Disorder (GAD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SPL-028 in Generalized Anxiety Disorder (GAD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SPL-028 in Generalized Anxiety Disorder (GAD) Drug Details: SPL-028 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CYB-004 in Social Anxiety Disorder (SAD/Social Phobia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CYB-004 in Social Anxiety Disorder (SAD/Social Phobia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CYB-004 in Social Anxiety Disorder (SAD/Social Phobia) Drug...
-
Product Insights
Social Anxiety Disorder (SAD/Social Phobia) – Drugs In Development, 2023
Global Markets Direct’s, ‘Social Anxiety Disorder (SAD/Social Phobia) - Drugs In Development, 2023’, provides an overview of the Social Anxiety Disorder (SAD/Social Phobia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Social Anxiety Disorder (SAD/Social Phobia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Generalized Anxiety Disorder (GAD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Generalized Anxiety Disorder (GAD) - Drugs In Development, 2023’, provides an overview of the Generalized Anxiety Disorder (GAD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Generalized Anxiety Disorder (GAD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Alcohol Addiction – Drugs In Development, 2023
Global Markets Direct’s, ‘Alcohol Addiction - Drugs In Development, 2023’, provides an overview of the Alcohol Addiction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alcohol Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Major Depressive Disorder – Drugs In Development, 2023
Global Markets Direct’s, ‘Major Depressive Disorder - Drugs In Development, 2023’, provides an overview of the Major Depressive Disorder pipeline landscape. The report provides comprehensive information on the therapeutics under development for Major Depressive Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-668 in Crohn’s Disease (Regional Enteritis)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ABBV-668 in Crohn's Disease (Regional Enteritis) Drug Details:ABBV-668 is under development for the treatment of crohn's...